Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 5/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164002 | 1.00 | DRD2 (0.42) | DRD2DRD3FUCA1IKBKBFDPS | |
| SCHEMBL4164000 | 1.00 | DRD2 (0.42) | DRD2DRD3FUCA1IKBKBFDPS | |
| Hydrochloric Acid SCHEMBL30636639 | 0.98 | DRD2 (0.43) | DRD2DRD3FUCA1IKBKBFDPS | |
| Hydrochloric Acid SCHEMBL15157347 | 0.98 | DRD2 (0.43) | DRD2DRD3FUCA1IKBKBFDPS | |
| SCHEMBL12506228 | 0.94 | FDPS (0.46) | DRD2DRD3FUCA1FDPSLMNA | |
| SCHEMBL13186048 | 0.94 | FDPS (0.46) | DRD2DRD3FUCA1FDPSLMNA | |
| SCHEMBL13207251 | 0.94 | FDPS (0.46) | DRD2DRD3FUCA1FDPSLMNA | |
| SCHEMBL31345184 | 0.86 | — | — | |
| SCHEMBL3335001 | 0.82 | CYP2D6 (0.42) | DRD2DRD3IKBKBFDPSFPR3 | |
| SCHEMBL14919306 | 0.82 | CYP2D6 (0.42) | DRD2DRD3IKBKBFDPSFPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317278-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3508482-B1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018040885-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2018-03-08 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | DRD2 1229/4885DRD3 487/4885FUCA1 3659/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DRD2 4692/4885DRD3 4636/4885FUCA1 1228/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | DRD2 3413/4885DRD3 3096/4885FUCA1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.